Plain-English translation of NCT04096014 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
This study doesn't follow the usual testing phases โ it may be an observational study or a different type of research.
This trial is testing whether Ensure Enlive, a protein supplement taken twice a day, can help prevent patients with advanced liver disease from being readmitted to the hospital. The study focuses on people who have already experienced hepatic encephalopathy โ a serious condition where liver disease causes confusion and brain symptoms. The researchers believe that extra protein at specific times of day may help preserve muscle strength and reduce the buildup of harmful substances in the body that trigger these symptoms.
Patients with advanced liver disease frequently return to the hospital because of hepatic encephalopathy, which is costly and disruptive to their lives. Current treatments don't prevent readmissions well enough, so doctors are exploring whether this medication can help by addressing one of the root causes โ the loss of muscle mass and buildup of ammonia in the blood.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
If you join this study, you will be randomly assigned to either receive the protein supplement (Ensure Enlive) twice daily or continue with your standard care. The study lasts 6 months, and you will likely have regular check-ins with the research team to track how you're doing and whether you're having any symptoms. You'll need to follow your assigned treatment plan and report any hospital visits or changes in your condition during this time.
AI-generated summary from trial data ยท Jun 15, 2026 ยท Not medical advice
United States